About Hyloris
Hyloris is a company based in Minneapolis (United States) founded in 2014. Hyloris has raised $16.29 million across 1 funding round from investors including Nomainvest, Noshaq and Saffelberg Investments. The company has 14 employees. Hyloris offers products and services including Maxigesic IV and Sotalol IV. Hyloris operates in a competitive market with competitors including Portola Pharma, Cellino, Arrakis Therapeutics, Flexion Therapeutics and Tenaya Therapeutics, among others.
- Headquarter Minneapolis, United States
- Employees 14
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website hyloris.com
- Social LinkedIn
- Total Equity Funding$16.29M (USD)
in 1 rounds
- Latest Funding Round$16.29M (USD), Series B
Apr 2020
- InvestorsNomainvest
& 2 more
- Employee Count14
Products & Services of Hyloris
Hyloris offers a comprehensive portfolio of products and services, including Maxigesic IV and Sotalol IV.
Intravenous drug for pain relief in medical settings.
Intravenous treatment for heart rhythm disorders.
Funding Insights of Hyloris
Hyloris has successfully raised a total of $16.29M through 1 strategic funding round. The most recent funding activity was a Series B round of $16.29 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.29M
- Total Rounds 1
- Last Round Series B — $16.29M
- First Round $16.29M
(Apr 2020)
- Investors Count 3
All 1 funding rounds of Hyloris with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | $16.29M | Series B | – | Noshaq, Saffelberg Investments | – |
3 investors in total: 3 institutional.
Investors in Hyloris
Hyloris has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Nomainvest, Noshaq and Saffelberg Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Noshaq is recognized as a Liège-based investment fund providing financing solutions. | – | noshaq.be | Liege, Belgium | |
- | – | saffelberg.com | - | |
Noel family investments are managed by this family office. | 1950 | nomainvest.eu | Eupen, Belgium |
Investor details for Hyloris
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Hyloris
13 people are tracked at Hyloris (8 in leadership, 5 in team); the tracked headcount is 14.
| Name | Role | Group |
|---|---|---|
Stijn Van Rompay | CEO | Leadership |
Dr. Dietmar Aichhorn | Chief Operating Officer | Leadership |
Dr. Prashant Choudhari | General Manager | Leadership |
Jean Luc Vandebroek | Chief Financial Officer, IR And Communication | Leadership |
Nicolaj Donskov Nielsen | Vice President, Portfolio Management | Leadership |
Genevieve Motte | VP Project Management | Leadership |
Christophe Lyssens | Vice President Clinical Affairs | Leadership |
Peter Mertens | HR Director | Leadership |
Michael Bennett | Project Manager | Team |
Catarina Pereira | Scientific Business Analyst | Team |
Véronique Verast | Quality Assurance Manager | Team |
Eric Chan | Expert Consultant | Team |
Rosario Ramón Albalate | Project Manager | Team |
Complete people profiles for Hyloris
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Hyloris
3 dated milestones of Hyloris across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Hyloris is founded.
- Funding First funding round of $16.3M.
- IPO Lists on the stock exchange (IPO).
Competitors of Hyloris
Hyloris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, Cellino, Arrakis Therapeutics, Flexion Therapeutics and Tenaya Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| portola.com | 2003 | San Francisco, United States | $296.09M | 369 | Therapeutics for cardiovascular and autoimmune diseases are developed. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| arrakistx.com | 2015 | Waltham, United States | $113M | 91 | Provider of tools for the analysis of RNA structures | |
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. | |
| zogenix.com | 2006 | Emeryville, United States | $149.06M | 159 | Drug delivery systems for CNS disorders and pain are developed. | |
| aegerion.com | 2005 | Cambridge, United States | $58.42M | 63 | Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed. | |
| cardurion.com | 2017 | Boston, United States | $270M | – | Therapeutics for heart and cardiovascular diseases are developed. | |
| herontx.com | 1983 | Redwood, United States | $32.14M | 21 | Reformulated injectables for chemotherapy side effects and pain are developed. |
Detailed competitors of Hyloris
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Hyloris
The website of Hyloris (hyloris.com) receives about 4K visits a month.
- Monthly visits4K
▲ 8% vs previous month
Latest news on Hyloris
Complete news archive for Hyloris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Hyloris
10 companies that operate in the same segment as Hyloris (Pain Management), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 | |
Therapeutics for migraine treatment are developed using nasal delivery. | 2016 | San Francisco, California, United States | USD 74.13 M | – | 24 | |
Pain treatment products are developed through reformulation technologies. | 2007 | Herzliya, Central District, Israel | USD 12 M | USD 17 K | 6 | |
Drug delivery systems for CNS disorders and pain are developed. | 2006 | Emeryville, California, United States | USD 149.06 M | – | – | |
Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment | 2010 | Bloomington, Indiana, United States | USD 530 M | USD 91.65 M | – | |
Therapies for pain and addiction treatment are developed. | 1977 | Saint-cloud, France | USD 248.09 M | USD 167.87 M | – | |
Novel drug products for chronic pain treatment are developed. | 2007 | Blue Bell, Pennsylvania, United States | USD 12.96 M | – | 17 | |
Abuse-deterrent extended-release therapeutics for chronic pain are developed. | 2002 | Canton, Ohio, United States | USD 103 M | USD 780.57 M | 357 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Hyloris
Hyloris was founded in 2014 and raised its 1st funding round 6 years after it was founded.
Hyloris is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
Stijn Van Rompay is the current CEO of Hyloris.
Hyloris is a funded company, having raised a total of $16.29M across 1 funding round to date. The company's 1st funding round was a Series B of $16.29M, raised on Apr 2020.
Hyloris has 14 employees.
Hyloris was founded in 2014 and is based in Minneapolis, United States. Focus is placed on pharmaceutical development for rare and orphan conditions. The pipeline includes Sotalol IV for arrhythmia, P-004 for inherited bleeding disorders, P-002 for pain management, and P-006 for oral mucositis. Generics such as Podofilox for vaginal warts and Dinoprostone for labor induction are also pursued in the sector.
Hyloris's top competitors include Flexion Therapeutics, Tenaya Therapeutics and Cellino.
Hyloris offers Maxigesic IV and Sotalol IV.
Hyloris has 3 investors. Key investors include Nomainvest, Noshaq, and Saffelberg Investments.